CA-170 – A Potent Small-Molecule PD-L1 Inhibitor or Not?

CA-170 is currently the only small-molecule modulator in clinical trials targeting PD-L1 and VISTA proteins – important negative checkpoint regulators of immune activation. The reported therapeutic results to some extent mimic those of FDA-approved monoclonal antibodies overcoming the limitations of...

Descripción completa

Detalles Bibliográficos
Autores principales: Musielak, Bogdan, Kocik, Justyna, Skalniak, Lukasz, Magiera-Mularz, Katarzyna, Sala, Dominik, Czub, Miroslawa, Stec, Malgorzata, Siedlar, Maciej, Holak, Tad A., Plewka, Jacek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6695792/
https://www.ncbi.nlm.nih.gov/pubmed/31374878
http://dx.doi.org/10.3390/molecules24152804

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6695792/
https://www.ncbi.nlm.nih.gov/pubmed/31374878
http://dx.doi.org/10.3390/molecules24152804

Ejemplares similares